Duchenne muscular dystrophy is an X-linked genetic disease in which mutations in the DMD gene stop muscle cells from making dystrophin, a structural protein that protects muscle fibers from tearing during contraction. Without it, muscle is destroyed faster than it can be repaired and is gradually replaced by fat and scar tissue. It affects roughly 1 in 3,500 to 5,000 newborn males worldwide, which works out to about 400 to 600 boys born with Duchenne or Becker muscular dystrophy in the United States each year.
There is no cure. But the treatment picture has changed more in the last decade than in the previous fifty years, and it is worth being precise about what is actually approved, what is still unproven, and where the myostatin drugs this site covers fit in. The short answer on that last point: myostatin inhibitors have failed repeatedly in Duchenne, and there is now a good biological explanation for why.
What causes Duchenne muscular dystrophy
The DMD gene sits on the X chromosome and is the largest gene in the human genome, spanning about 2.5 million base pairs across 79 exons. It encodes dystrophin, a 427 kDa protein that anchors the internal cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the dystrophin-glycoprotein complex. That link acts as a shock absorber. Every time a healthy muscle contracts, dystrophin distributes the mechanical stress so the cell membrane does not tear.
Because the gene is on the X chromosome and the inheritance is recessive, the disease overwhelmingly affects males, who have only one copy. Female carriers usually have milder or no symptoms, though they can experience muscle weakness and cramping and carry an elevated risk of cardiomyopathy, which is why carrier testing and cardiac screening matter for female relatives.
The distinction between Duchenne and the milder Becker muscular dystrophy comes down to the reading frame. Mutations that shift the genetic reading frame produce a prematurely truncated, non-functional protein and cause Duchenne. Mutations that delete material but leave the reading frame intact allow a shortened but partly functional dystrophin, producing Becker. This "reading frame rule" holds in roughly 90 percent of cases, not all of them, which is one reason genetic results sometimes do not predict severity cleanly.
That rule is also the entire basis for exon-skipping drugs, covered below.
Symptoms and how Duchenne progresses
Weakness typically appears in early childhood, often between ages 2 and 5. Early signs are proximal: difficulty running, climbing stairs, or rising from the floor, frequent falls, toe walking, and enlarged-looking calves from fatty infiltration. Many boys use a Gowers maneuver, pushing on their thighs with their hands to stand up.
Weakness is progressive. Without treatment, boys historically lost the ability to walk around age 10. Cardiomyopathy typically begins in adolescence, as the heart muscle is affected by the same dystrophin deficiency, and the diaphragm and other respiratory muscles weaken in parallel. Historically, males with Duchenne lived into their twenties. Cardiac and respiratory care, including assisted ventilation and cardiac medications, has extended that meaningfully, and survival statistics from older cohorts understate what current standards of care achieve.
Cognitive and learning differences are more common in Duchenne than in the general population, because dystrophin isoforms are also expressed in the brain. This is not universal and varies with the mutation's position in the gene.
For the diagnosis coding side, Duchenne and Becker share the ICD-10-CM code G71.01, a distinct code created specifically so these dystrophinopathies could be tracked separately from other muscular dystrophies. Our muscular dystrophy ICD-10 guide breaks down the related codes.
How Duchenne is diagnosed
Diagnosis usually starts with a serum creatine kinase test. CK leaks out of damaged muscle, and in Duchenne it is typically elevated to many times the normal range, often before symptoms are obvious. A markedly raised CK in a young boy with motor delay is the signal to move to genetic testing.
Genetic testing confirms the diagnosis and defines the mutation. Deletion and duplication analysis catches the majority of cases; sequencing finds point mutations and small changes in the rest. Getting the exact mutation is not academic. It determines eligibility for exon-skipping drugs, for nonsense-mutation approaches, and for most clinical trials. Muscle biopsy, once standard, is now used mainly when genetic testing is inconclusive.
Duchenne is not the only inherited muscle disease that presents with proximal weakness in childhood. Limb-girdle muscular dystrophy can look similar early on, which is another argument for genetic confirmation rather than clinical impression alone.
FDA-approved treatments for Duchenne
Corticosteroids remain the backbone. Prednisone and deflazacort (Emflaza) slow functional decline, and the effect on walking is substantial. In the CINRG Duchenne Natural History Study, median age at loss of ambulation was 10.23 years for glucocorticoid-naive patients, 12.02 years with prednisone or prednisolone, and 13.95 years with deflazacort. The tradeoff is real: weight gain, growth suppression, bone fragility, and behavioral effects. Choice of agent, dose, and schedule is a prescriber's decision made with a neuromuscular specialist.
Vamorolone (Agamree) was approved in October 2023 for patients 2 years and older. It is a dissociative steroid designed to keep anti-inflammatory benefit while reducing the bone, growth, and behavioral side effects of conventional corticosteroids.
Givinostat (Duvyzat) was approved in March 2024 for patients 6 and older. It is a histone deacetylase inhibitor and the first nonsteroidal drug approved for Duchenne regardless of which mutation a patient carries. Its approval rested on a single trial of 179 male patients.
Exon-skipping antisense oligonucleotides are mutation-specific. Four are approved: eteplirsen (Exondys 51, 2016) and golodirsen (Vyondys 53, 2019), viltolarsen (Viltepso, 2020), and casimersen (Amondys 45, 2021). They mask a target exon during RNA splicing so the reading frame is restored and a shortened, Becker-like dystrophin is produced. Each drug only helps patients whose specific mutation is amenable to skipping that exon, so any given drug serves a minority of the Duchenne population.
An important caveat: all four received accelerated approval based on dystrophin production as a surrogate marker, not on proven functional benefit. The confirmatory ESSENCE trial, which randomized 228 ambulatory boys amenable to exon 45 or 53 skipping, did not meet its primary endpoint of change in four-step ascend velocity at week 96, with a least-squares mean difference of 0.06 steps per second versus placebo. Numerical trends favored treatment and safety was acceptable, but the confirmatory functional evidence these approvals were meant to produce has not materialized cleanly.
Gene therapy. Delandistrogene moxeparvovec (Elevidys) delivers a shortened micro-dystrophin gene via an AAV vector. Its label has since been restricted. In November 2025 the FDA added a boxed warning for serious liver injury and acute liver failure, including fatal outcomes, and narrowed the indication to ambulatory patients 4 years and older with a confirmed DMD mutation, removing non-ambulatory patients entirely. The action followed reports of fatal acute liver failure in non-ambulatory boys treated with the therapy. The current label requires weekly liver function monitoring for at least three months after infusion and advises patients to remain near an appropriate medical facility for at least two months.
Why myostatin inhibitors keep failing in Duchenne
Myostatin is the body's brake on muscle growth. Blocking it makes animals visibly more muscular, so Duchenne looked like an obvious target: if you cannot fix the dystrophin defect, at least build more muscle to compensate. Eight major programs tried, including domagrozumab, ACE-031, landogrozumab, and taldefgrobep alfa. None produced a functional benefit in boys with Duchenne. We covered that trial history in detail in myostatin and Duchenne muscular dystrophy.
The most compelling explanation is that the pathway being targeted is already switched off. A 2017 Nature Communications analysis of muscle from patients with neuromuscular disease found that in Duchenne muscle, only about 8 percent of normal GDF8 (myostatin) mRNA was detectable, circulating myostatin sat at roughly 50 percent of control levels, the activin receptor ACVR2B was down to about 30 percent residual mRNA, and follistatin, myostatin's natural antagonist, was nearly doubled at about 189 percent of controls.
In other words, dystrophic muscle has already suppressed myostatin signaling on its own. The authors concluded that further inhibiting a pathway that is already strongly downregulated in severely affected muscle is unlikely to be an efficient strategy, and that the underlying genetic defect probably has to be corrected first.
This is also a caution about mouse data. Mice carry higher circulating myostatin and downregulate it less in disease states, so the dramatic mdx mouse results never had a human counterpart to reproduce. If you are reading about follistatin or myostatin as a muscular dystrophy strategy, this is the single most important piece of context.
What is still in development
The active frontier is dystrophin restoration rather than muscle bulking. Next-generation exon-skipping conjugates from Avidity Biosciences and Dyne Therapeutics use antibody-oligonucleotide delivery to get more drug into muscle, and both have been discussed as candidates for accelerated approval. Additional AAV micro-dystrophin programs, including Regenxbio's RGX-202, remain in clinical development. Gene editing approaches are earlier stage.
Because regulatory status in this field changes quickly and several of these programs are in active review, treatment eligibility should be confirmed with a neuromuscular specialist rather than from any article, including this one.
Frequently asked questions
Is Duchenne muscular dystrophy fatal? Yes. It is a progressive disease with no cure, and death typically results from cardiac or respiratory complications. Historically, males lived into their twenties. Corticosteroids, assisted ventilation, and cardiac management have extended survival beyond the figures reported in older natural history cohorts.
Can girls get Duchenne muscular dystrophy? It is rare but possible. Because the inheritance is X-linked recessive, females typically need mutations affecting both copies to be fully affected. Carrier females can have milder muscle symptoms and an increased risk of cardiomyopathy, so cardiac screening is recommended for them.
What is the difference between Duchenne and Becker muscular dystrophy? Both come from mutations in the same DMD gene. Duchenne results from mutations that disrupt the reading frame and eliminate functional dystrophin. Becker results from mutations that preserve the reading frame, allowing a shortened but partly working protein, so onset is later and progression slower.
Do myostatin inhibitors work for Duchenne muscular dystrophy? No approved myostatin inhibitor exists for Duchenne, and multiple large trials failed to show functional benefit. Research indicates myostatin signaling is already heavily suppressed in dystrophic muscle, which likely limits how much additional blockade can accomplish.
Does gene therapy cure Duchenne? No. Current AAV gene therapy delivers a shortened micro-dystrophin rather than the full-length protein, and it is not a cure. Elevidys now carries a boxed warning for acute liver failure and is approved only for ambulatory patients aged 4 and older.